 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || Trial completion date, Trial primary completion date, Metastases: A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (clinicaltrials.gov) - May 24, 2024
P1/2, N=506, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Dec 2025 --> Aug 2026 | Trial primary completion date: Dec 2025 --> Aug 2026
- | TPST-1120 / Tempest Therap, Opdivo (nivolumab) / Ono Pharma, BMS
Journal, Combination therapy, Monotherapy, Metastases: First-in-Human Phase I Trial of TPST-1120, an inhibitor of PPAR?, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors. (Pubmed Central) - Mar 29, 2024
P1
Trial completion date: Dec 2025 --> Aug 2026 | Trial primary completion date: Dec 2025 --> Aug 2026 TPST-1120 was well tolerated as monotherapy and in combination with nivolumab and the combination showed preliminary evidence of clinical activity in PD-1 inhibitor refractory and immune compromised cancers.
- TPST-1120 / Tempest Therap, Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
PPAR-? antagonist enhances immunotherapy and anti-angiogenic therapy to inhibit murine renal cancer (Section 18) - Mar 5, 2024 - Abstract #AACR2024AACR_5661;
Importantly, we demonstrate that TPST-1120 can reverse an immunosuppressive class of immune cells to promote anti-tumor immunity and anti-angiogenesis in kidney cancer in the absence of overt toxicity. These data support advancement of TPST-1120 into RCC.
- TPST-1120 / Tempest Therap, Opdivo (nivolumab) / Ono Pharma, BMS
Pharmacodynamics and gene expression analysis of patients with renal cell carcinoma treated with combination nivolumab and TPST-1120 in a phase I clinical trial (NCT03829436). (Level 1, West Hall; Poster Bd # H20) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_781;
P1
Novel therapies on this clinical scenario are needed. On this abstract we showed radiographic and pharmacodynamic data on patients with RCC who achieved a clinical partial response by RECIST on the phase I clinical trial TPST1120-001.
- || amezalpat (TPST-1120) / Tempest Therap
Trial completion, Enrollment change, Trial completion date, Combination therapy, Monotherapy, Metastases: TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers (clinicaltrials.gov) - Jul 3, 2023
P1, N=38, Completed, Sponsor: Tempest Therapeutics
On this abstract we showed radiographic and pharmacodynamic data on patients with RCC who achieved a clinical partial response by RECIST on the phase I clinical trial TPST1120-001. Active, not recruiting --> Completed | N=138 --> 38 | Trial completion date: Jun 2024 --> Sep 2022
- ||||| TPST-1120 / Tempest Therap, Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Clinical: 🔥Tempest announces early results for combination of TPST-1120 with Atezo/Bev in 1st line HCC ✅TPST-1120 -> PPARα agonist 🔎phs 1b/2, 70 pts 👉ORR 30% vs 17% (lower than expected in AB arm) 🧐Promsing, are we on the way to triplet Tx in HCC? @myESMO @EASLedu #livertwitter… https://t.co/0S6Uof68sN (Twitter) - Apr 29, 2023
- TPST-1120 / Tempest Therap
Lipid and immune-based biomarkers associated with clinical response to TPST-1120: A small molecule antagonist of peroxisome-proliferator activated receptor-alpha (Section 39; Poster Board #4) - Mar 14, 2023 - Abstract #AACR2023AACR_3428;
P1
Increased frequencies of responding patients bearing PI3K pathway or IDH mutations may reveal populations likely to benefit from treatment with TPST-1120. 1.
- || Trial completion date, Trial primary completion date, Metastases: A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (clinicaltrials.gov) - Jan 23, 2023
P1/2, N=320, Recruiting, Sponsor: Hoffmann-La Roche
1. Trial completion date: Jul 2025 --> Dec 2025 | Trial primary completion date: Jul 2025 --> Dec 2025
- TPST-1120 / Tempest Therap
Pharmacodynamic and predictive biomarkers associated with response in cancer patients treated with TPST-1120: a first-in-class, small molecule antagonist of Peroxisome-Proliferator Activated Receptor-Alpha (Hall C) - Nov 2, 2022 - Abstract #SITC2022SITC_1832;
P1
Patients with PR demonstrated gene expression changes that implicate immune activation and alleviation of immune suppression as potential biomarkers of clinical benefit. Increased frequencies of responding patients bearing PI3K pathway or IDH mutations may reveal populations likely to benefit from treatment with TPST-1120.
- || Trial completion date, Trial primary completion date, Metastases: A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (clinicaltrials.gov) - Sep 9, 2022
P1/2, N=320, Recruiting, Sponsor: Hoffmann-La Roche
Increased frequencies of responding patients bearing PI3K pathway or IDH mutations may reveal populations likely to benefit from treatment with TPST-1120. Trial completion date: Dec 2024 --> Jul 2025 | Trial primary completion date: Dec 2024 --> Jul 2025
- || amezalpat (TPST-1120) / Tempest Therap
Enrollment closed, Trial primary completion date, Combination therapy, Monotherapy, Metastases: TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers (clinicaltrials.gov) - May 2, 2022
P1, N=138, Active, not recruiting, Sponsor: Tempest Therapeutics
Trial completion date: Dec 2024 --> Jul 2025 | Trial primary completion date: Dec 2024 --> Jul 2025 Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2022 --> Jul 2022
- TPST-1120 / Tempest Therap, Opdivo (nivolumab) / Ono Pharma, BMS
A phase 1 study of TPST-1120 as a single agent and in combination with nivolumab in subjects with advanced solid tumors. (Available On Demand) - Apr 28, 2022 - Abstract #ASCO2022ASCO_5222;
P1
The drug is well tolerated as a single agent and in combination with nivolumab. Promising objective responses have been observed in combination with nivolumab in subjects previously refractory to anti-PD-1 therapy, including 2/2 responders in late-line RCC, and a subject with heavily pretreated CCA, a tumor type generally not responsive to anti-PD-1 alone.
- || Trial completion date, Trial primary completion date, Metastases: A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (clinicaltrials.gov) - Apr 11, 2022
P1/2, N=280, Recruiting, Sponsor: Hoffmann-La Roche
Promising objective responses have been observed in combination with nivolumab in subjects previously refractory to anti-PD-1 therapy, including 2/2 responders in late-line RCC, and a subject with heavily pretreated CCA, a tumor type generally not responsive to anti-PD-1 alone. Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Jul 2024 --> Dec 2024
- || Trial completion date, Metastases: A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (clinicaltrials.gov) - Aug 26, 2021
P1/2, N=280, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Jul 2024 --> Dec 2024 Trial completion date: Oct 2024 --> Jul 2024
- ||| Enrollment change, Trial completion date, Trial primary completion date, Metastases: A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (clinicaltrials.gov) - May 9, 2021
P1/2, N=280, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date: Oct 2024 --> Jul 2024 N=100 --> 280 | Trial completion date: Jul 2024 --> Oct 2024 | Trial primary completion date: Oct 2021 --> Jul 2024
- |||| New P1/2 trial, Metastases: A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (clinicaltrials.gov) - Aug 23, 2020
P1/2, N=100, Recruiting, Sponsor: Hoffmann-La Roche
- || amezalpat (TPST-1120) / Tempest Therap
Enrollment change, Combination therapy, Monotherapy, Metastases: TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers (clinicaltrials.gov) - Jun 23, 2020
P1, N=138, Recruiting, Sponsor: Tempest Therapeutics
N=100 --> 280 | Trial completion date: Jul 2024 --> Oct 2024 | Trial primary completion date: Oct 2021 --> Jul 2024 N=338 --> 138
- TPST-1120 / Tempest Therap, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
Phase 1/1b Multicenter Trial of TPST-1120, a Peroxisome Proliferator-Activated Receptor Alpha (PPARĪ±) Antagonist as a Single Agent (SA) or in Combination in Subjects with Advanced Cancers (Prince George's Exhibition Halls AB) - Oct 2, 2019 - Abstract #SITC2019SITC_801;
We have initiated a phase 1/1b multicenter, open label trial to evaluate TPST-1120 as a SA and in combination (combo) with other systemic therapies including nivolumab, an anti-PD1 monoclonal antibody; docetaxel, a cytotoxic chemotherapeutic agent and cetuximab, an anti-EGFR monoclonal antibody. N/A
- | amezalpat (TPST-1120) / Tempest Therap
Enrollment open, Combination therapy, Monotherapy, Metastases: TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers (clinicaltrials.gov) - Apr 1, 2019
P1, N=338, Recruiting, Sponsor: Tempest Therapeutics
N/A Not yet recruiting --> Recruiting
- | amezalpat (TPST-1120) / Tempest Therap
New P1 trial, Combination therapy, Monotherapy, Metastases: TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers (clinicaltrials.gov) - Feb 4, 2019
P1, N=338, Not yet recruiting, Sponsor: Tempest Therapeutics